Buval'tsev V I, Spasskaia M B, Nebieridze D V, Metel'skaia V A, Guseva O I
Klin Med (Mosk). 2003;81(7):51-5.
An open, comparative, cross-over 8-week trial of beta-blockers nebivolol and metoprolol in 30 patients with arterial hypertension (AH) studied the office, ambulatory blood pressure and heart rate levels, endothelium-dependent vasorelaxation, endothelial NOS and NO production. It was found that nebivolol activated the system eNOS-NO and improved vasomotor parameters of the endothelium. Metoprolol failed to activate enzyme eNOS activity and NO production to the same level and did not improve the endothelial vasomotor function. The antihypertensive activity of nebivolol was higher than that of metoprolol. Thus, nebivolol can be used in patients with AH and cardiovascular risk factors to correct endothelial dysfunction.
一项针对30例动脉高血压（AH）患者的开放、比较性、交叉8周试验，研究了奈必洛尔和美托洛尔这两种β受体阻滞剂对诊室血压、动态血压及心率水平、内皮依赖性血管舒张、内皮型一氧化氮合酶（eNOS）及一氧化氮（NO）生成的影响。结果发现，奈必洛尔激活了eNOS-NO系统，改善了内皮的血管舒缩参数。美托洛尔未能将eNOS活性和NO生成激活至相同水平，也未改善内皮血管舒缩功能。奈必洛尔的降压活性高于美托洛尔。因此，奈必洛尔可用于患有AH及心血管危险因素的患者，以纠正内皮功能障碍。
